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1. In tro d u ctio n
1 .1 .T h e  freq u e n cy  o f  b ir th  d efects
In developed or high income countries the estimated rate of abnormal fetal and neonatal 
conditions at birth is four per cent. However, the rate of birth defects is different in developed, 
developing and underdeveloped countries ranging from 4% up to 7,9% according to a newly 
conducted world-wide study carried out by the March of Dimes Birth Defects Foundation(T).
In the developed countries the following numbers have to be considered. Out of the 4 per cent 
general rate of abnormal fetal conditions 0,8 per cent are chromosomal abnormalities, 1 per 
cent are monogenic disorders, 2,2 per cent are structural abnormalities (Table 1)(2).
Table 1 Annual Rate of Birth Defects in the Globe (WHO)
Annual Rate of Birth Defects in the Globe
Total no. of birth in the world 130 000 000
Congenital anomalies: 3 200 000
Chromosomal anomalies: 850 000
Mendelian disorders: 900 000
Haemoglobinopathies: 250 000
Total: 5 200 000 (4% )
Couples deciding to have a child rightly lay claim to have a healthy baby. Therefore, they turn 
to the obstetrician or to the nearest medical genetic service to have the answer, if  their future 
baby will be healthy. To answer the question correctly the available prenatal counselling, 
screening and diagnostic methods can be used.
1 .2 .P r im a ry  an d  se co n d a ry  p rev en tio n
Seventy per cent of neural tube defects can be prevented primarily by periconceptional folate 
admininistration. The 70% prevention rate of neural tube defects achieved by the only 
administration of folic acid, can be further increased by adding choline, betaine and inositol to 
folates, especially in obese women (3). However, the majority of abnormal fetal conditions 
can not be prevented primarily. This is especially true for chromosomal aneuploidies, which 
can be prevented by secondary measures such as preimplantation genetic diagnosis (PGD), 
prenatal screening (PS) and prenatal diagnosis (PD).
Before the introduction of intrauterine diagnostics the fetal abnormalities could only be 
detected after birth or in the neonatal period. However, during the last decades a great 
development has been experienced in prenatal screening and diagnosis of birth defects. The 
introduction of high resolution ultrasound, fetal biochemistry and new achievements in 
maternal and fetal pathophysiology equally contributed to the formation of a new independent 
field of science, the fetal medicine.
1 .2 .1 . P re im p la n ta tio n  g en e tic  d iagn o sis.
Pre-implantation genetic diagnosis (PGD) is generally defined as the in vitro testing the 
embryo before embryo transfer and its implantation.
1 .2 .2 . P r e n a ta l  scre en in g  o r  n o n -in v a siv e  m eth od s.
Prenatal screening (PS) for fetal malformations means to detect embryos or fetuses with 
normal or abnormal features during their intrauterine life. The methods of PS has been 
developed during the last decades by recognizing ultrasound soft markers and maternal blood 
biochemical characteristics of the affected pregnancies. Neither fetal sampling nor 
transuterine puncture is applied therefore, the non-invasive term can also be used. To achieve 
an efficient screening the whole pregnant population should have been examined with the 
methods of the possible highest detection rate and at the lowest cost. The recently advocated 
methods to identify affected pregnancies are the ultrasound anatomy scan and the maternal 
blood tests. To evaluate the efficacy of a particular screening method one has to calculate 
sensitivity, specificity, detection rate, positive and negative predictive values and cut off 
values.
To evaluate the efficacy of a particular screening method one has to calculate sensitivity, 
specificity, detection rate, positive and negative predictive values, and cut off values.
Sensitivity (detection rate, true positive rate): measures the proportion of actual positives 
which are correctly identified as true positives. Specificity (true negative rate): measures the 
proportion of negatives which are correctly identified as true negatives.
Positive predictive value (PPV): proportion of positive results that are true positives. 
Negative predictive value (NPV): proportion of negative results that are true negatives.
False negative rate and false positive rate (cases) should be as low as possible. I f  the test is 
screen negative one should be very careful since this does not mean that the method 
completely picked up the affected cases, only the estimated risk is below the cut off.
Cut off value is a term at what level of risk is considered to be screen positive where invasive 
diagnostics is offered. In many countries the threshold of cut off value for high-risk is under 
1:250-300. In Hungary, the level of intervention is 1:150, or the presence of two ultrasound 
soft markers or more. The risk of aneuploidy and risk of postprocedural miscarriage is 
subjective and relative; Some couples may decide to have amniocentesis at a 1:1000 risk of 
trisomy 21, while others would not opt for an invasive procedure even if  they had a 1:10 risk 
score.
1 .2 .2 .1 . P r e n a ta l  d iag n osis o r  in v asiv e  m eth od s
Prenatal diagnosis enables a definitive fetal diagnosis usually through fetal sampling and 
laboratory examination of the sampled material (chorionic villi, amniotic fluid, fetal blood 
and/or tissue). Because of the needle puncture for sampling the invasive prenatal method is 
the other term used. The disadvantage of the sampling procedure is the 1% procedural risk of 
abortion, while the advantage is the certainty of the result which is nearly 100 per cent sure. 
Because of the procedural risk of miscarriage associated with invasive method, couples 
usually first decide to have a non-invasive prenatal screening test to estimate the risk of a fetal 
chromosomal abnormality if  it is high enough to justify the fetal loss risk. 
Recent Guideline of the Hungarian College of Clinical Geneticist and of Obstetrics and 
Gynecology (2010) recommend that all pregnant women of 37 years of age or over be offered 
invasive testing to obtain a definitive diagnosis of fetal karyotype. However, from ethical
point of view the couples are let to have an autonome decision if  they want to have an 
invasive test or not. At genetic counselling the patient is advised with the possibility that they 
can skip the expensive screening and can go straight for invasive testing.
1.2.2.2. Prenatal genetic counseling (PGC)
Prenatal screening and diagnosis is not an obligatory medical service like preventing 
infectious diseases by immunization and vaccination. PS and PD can be offered only through 
genetic counselling, which is a communication process between the pregnant patients (couple) 
and the counsellor providing up to date information about the fetal condition and the recent 
choices of fetal diagnosis (4). The aim of prenatal genetic counselling is to plan timely 
medical or surgical treatment of abnormal fetal conditions via screening and diagnosis during 
pregnancy or after birth. An other purpose of prenatal counselling to provide information to 
the parents to have a decision about their fetus in time. As a result of counselling the couple 
will be able to prepare psychologically, socially, financially, and medically for a baby with a 
health problem or disability. For example, Down Syndrome is associated with cardiac defects 
that may need intervention immediately upon birth (Table 2).
Table 2 Methods of prenatal screening and diagnosis
INVASIVE (DIAGNOSTICS) NON- INVASIVE (SCREENING)
1. CHORION-BIOPSY 
Chorionic Villus Sampling (CVS)
1. ULTRASOUND
I. TRIMESTER
II. TRIMESTER
2. AMNIOCENTESIS 2. MATERNAL SERUM MARKERS
I. TRIMESTER
II.TRIMESTER
3. CORDOCENTESIS Fetal DNA in maternal blood and NIPT
RISK: ~ 1 % RISK: 0 %
2. The Down syndrome
2 .1 .T h e  p re v a le n c e , th e  d isco v ery , an d  s c re e n in g  o f  D ow n sy n d ro m e
The Down syndrome is the most frequent numerical chromosomal abnormality also known as 
trisomy 21. It results in severe developmental errors, physical and mental handicaps, which 
can be present already in the fetal life (5). At present, it can not be cured or effectively treated. 
Therefore, the prevention by early diagnosis and therapeutic abortion is the only choice.
The Down syndrome was first described by Dr. John Langdon Down in 1886 (6). The fact 
that trisomy 21 is the cause of Down-syndrome was invented by Dr. Jerome Lejuene in 1959. 
The truth is that Marte Gautier, a woman pediatrician discovered it in 1957. Lejeune only 
discovered the laboratory where the discovery of 47 chromosome was made by Dr Marthe 
Gautier using a new tissue culture technique brought back from the United States (7). 
Anyway, it was an intellectual theft by Jerome Lejuene.
The association between maternal age and increasing prevalence of Down-syndrome was first 
discovered by Suttleworth in 1906 and subsequently confirmed by others (8). The increase in 
prevalence of Down syndrome after 35 years of age was considered to be worth for indication 
for karyotyping of the suspected fetus by amniocentesis (AC) or chorionic villus sampling 
(CVS) (Figure 1).
Figure 1 Age related-risk of Down syndrome
Risk for Down Syndrome and Other Trisomies by Maternal Age
SOURCES:
Hook EB. Cross PK. Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 1983:249 (15):2034-3 S. 
Nevrberser. D .: Down Svndrome: Prenatal Risk Assessment and Diasnosis. American Family Physician. 2001.
Down syndrome births in the United States from 1989 to 2001. Egan JF - Am J Obstet Gynecol - 01-5EP-2004: 191(3): 1044-8.
Table 3 Risk of Down Syndrome and other chromosome abnormalities in Live births by
Maternal age
Risk of Down Syndrome and Other Chromosome Abnormalities in Live Births by Maternal Age
RISK RISK RISK
MATERNAL
AGE
(AT TERM)
DOWN
SYNDROME
TOTAL
CHROMOSOME
ABNORMALITY
MATERNAL
AGE
(AT TERM)
DOWN
SYNDROME
TOTAL
CHROMOSOME
ABNORMALITY
MATERNAL
AGE
(AT TERM)
DOWN
SYNDROME
TOTAL
CHROMOSOME
ABNORMALITY
25 1 1n 1.250 1 in 476 32 1 in 637 1 in 323 39 1 in 125 1 in 81
26 1 1n 1.190 1 in 476 33 1 in 535 1 in 286 40 1 in 94 1 in 63
27 1 in 1.111 1 in 455 34 1 in 441 1 in 224 41 1 in 70 1 in 49
28 1 in 1,031 1 in 435 35 1 in 356 1 in 179 42 1 in 52 1 in 39
29 1 in 935 1 in 417 36 1 in 281 1 in 149 43 1 in 40 1 in 31
30 1 in 840 1 in 385 37 1 in 217 1 in 123 44 1 in 30 1 in 21
31 1 in 741 1 in 385 38 1 in 166 1 in 105 >45 >1 in 24 2 1  in 19
Source: Hecht CA and Hook EB 1996
The prevalence of trisomy 21 is 1.3/1000 at birth in developed high income countries. In 
middle- and low-income countries without prenatal screening services the percentage of
women of advanced maternal age (greater than 35 years of age) delivering infants is high 
(average 12-20 percent) (Table 3). The birth prevalence of Down syndrome can reach 2-3 per 
1,000 in these countries: a rate approximately double that currently seen in high-income 
countries. The demography of motherhood in the western world has shifted strikingly in the 
past two decades. A new tendency can be observed, that women continue having children up 
to the end of reproductive life, consequently the birth incidence of chromosomal disorders are 
increasing by facing new challenges to prenatal diagnosis. (1)
Advanced paternal age (greater than 35 years of age), although associated with an increased 
rate of mutations and a slightly higher birth prevalence of autosomal dominant disorders, is 
not considered a significant influence on the overall birth prevalence of birth defects. (1)
On the base of maternal age approximately 30% of fetal Down syndrome could be detected 
through invasive procedures, if  all women over 35 years (5%) would participate in this 
diagnostics. However, invasive procedures have one per cent risk of abortion and can not be 
offered to all women. To avoid fetal loss due to invasive tests stimulated the development of 
new, not risky screening techniques for defining pregnancies with high and low risk for 
chromosomal abnormalities.
2 .2 .O th er tr is o m ie s : E d w ard s sy n d ro m e: tr iso m y  1 8  an d  B a r th o lin -P a ta u  
sy n d ro m e: tr is o m y  13
The second and third most frequent chromosomal trisomies after Down syndrome are the 
Edwards syndrome (the trisomy 18), and Bartholin-Patau syndrome (the trisomy 13), 
respectively. They also show an association with advanced maternal age (Figure 1). In 15 per 
cent of the cases they can be carried to term. In 85 % of the cases the trisomy leads to 
intrauterine death during the antenatal period (9-11).
2 .3 .P r e n a ta l  (u ltra so u n d ) s c re e n in g  o f  D ow n sy n d ro m e.
With the introduction of the higher resolution vaginal probes ultrasound studies of the 
embryonic and fetal structures was initiated in the second half of the 80ies. A quite new 
observation about the association between the first trimester increased nuchal fluid 
accumulation (also known as nuchal translucency, NT) and fetal Down syndrome was 
reported (Szabo and Gellen) in 1990 (12). This observation was approved on a larger pregnant 
population by Nicolaides et al, 1992 (9, 13). The measurement of NT was standardized and
has become the basis of first trimester screening for Down syndrome. The next step in 
screening for trisomy 21 is the risk calculation based on maternal age and NT thickness. The 
sensitivity of this first trimester screening was 80% to 90% in different hands. Subsequently, 
maternal blood biochemical markers such as free beta-human chorionic gonadotropin (free B- 
hCG), and pregnancy associated plasma protein-A (PAPP-A) and other additional ultrasound 
markers (presence or absence of nasal bone, tricuspidal and ductus venosus flow) was added 
to the first trimester screening test further increasing the sensitivity up to 93-95% at a 2,5% 
fals positive rate (Table 4).
Table 4 The efficacy of different screening methods for trisomy 21
The efficacy of different screening methods for trisomy 21
Screening method Sensitvity
(%)
Fals-positive rate 
(%)
MA (maternal age) 30 5
First trimester
MA + NT 75-80 5
MA + NT + free P-hCG + PAPP-A (combined test) 85-95 5
Combined test + NB + tricuspidal or ductus venosus flow 93-96 2,5
Second trimester
MA + se. AFP + hCG (double test) 55-60 5
MA + se. AFP + free P-hCG (double test) 60-65 5
MA + se. AFP, hCG, uE3 (triple test) 60-65 5
MA + se. AFP, free P-hCG, uE3 (triple test) 65-70 5
MA + se. AFP, hCG, uE3, inhibin A (quadriple test) 65-70 5
MA + se. AFP, free P-hCG, uE3, inhibin A (quadruple test) 70-75 5
MA + NT + PAPP-A (11-13. weeks) + quadriple test 
(integrated test) 90-94 5
Second trimester ultrasound signs 70 5-15
MA =  maternal age; NT =  nuchal translucency; N B =  nasal bone 
p-hCG: p-human choriongonadotropin; PAPP-A =  pregnancy-associated plasma protein-A 
(Source: Nicolaides, K. H.:Screening for fetal aneuploidies at 11 to 13 weeks. Prenat. Diagn., 2011, 3 1 ,7 -1 5 .)
Despite the multitude of ultrasound soft markers for Down syndrome fetuses -  such as 
increased nuchal fold thickness, cystic hygroma, cardiac anomalies, echogenic intracardiac 
foci, nasal bone hypoplasia, ventriculomegaly, widened iliac crest angle, short 
femur/humerus, duodenal atresia, echogenic bowel, pyelectasis-hydronephrosis, sandal gap 
sign, choroid plexus cyst, and midphalanx hypoplasia of the fifth finger there are no sensitive 
ultrasound markers in the second trimester that can be used either alone or in combination.
Furthermore, these markers may not be present in all affected fetuses, and such as all soft
markers, they can also be detected in euploid cases (14) (Table 5).
Table 5 Ultrasound soft markers for Down syndrome fetuses in the second trim ester (14)
Nuchal fold thickness (NF)
Cystic hygroma 
Cardiac anomalies 
Echogenic intracardiac foci/golf ball 
Nasal bone hypoplasia (NBL)
Increased prenasal thickness (PT)
Ventriculomegaly 
Pyelectasis-hydronephrosis 
Duodenal atresia 
Echogenic bowel 
Sandal gap sign 
Choroid plexus cyst 
Midphalanx hypoplasia of the fifth 
Dilatrd cavum septi pellucidi 
Widened iliac crest angle 
Short femur
Short humerus
2 .4 .P re lim in a ry  o b se rv a tio n s
During the last decades the evaluation of the nasal bone length (NBL) (15-18), its presence, 
absence or hypoplasia was suggested in second trimester euploid and trisomy 21 fetuses (15, 
17-25). Furthermore, a detailed analysis of the facial profile revealed the significance of the 
prenasal soft tissue thickness (PT) (26, 27) as an efficient sonographic marker potentially 
applicable for ultrasound detection of second trimester trisomy 21 fetuses. Preliminary 
observation suggested that PT combining with NBL as a ratio would increase the detection 
rate of second trimester Down-syndrome (28-32).
Our preliminary observations using 2D ultrasound measurements of NBL and PT at our 
tertiary referral center suggested the potential for the second-trimester identification of 
euploid and Down syndrome fetuses in a mixed-risk population (33,34).Considering the data 
from the literature and our good experience with the PT-to-NBL and NBL-to-PT ratio for 
screening for trisomy 21, a study was started from January 2008 and these markers were 
incorporated into our second trimester fetal anomaly scan. This prospective study examined 
the clinical value of 2D ultrasound measurements of NBL, PT, and their ratios for 
differentiating euploid and Down syndrome fetuses in the second trimester (in an at-risk 
population).
3 . A im s o f  th e  study
1) To analyse fetal facial profile for finding new second-trimester markers for Down- 
syndrome screening.
2) To study the feasibility of the measurements of the fetal nasal bone length (NBL) and 
prenasal thickness (PT) during the second trimester anatomy scan.
3) To create normograms of fetal nasal bone length (NBL), prenasal thickness (PT) and 
their ratios for euploid second trimester fetuses.
4) To study the developmental characteristics of PT and NBL in a large second trimester 
pregnant population to improve the understanding and clinical usage of the 
normograms.
5) To determine whether the increase in nasal bone length (NBL) and prenasal thickness 
(PT) between 14-28 weeks of gestation is parallel or divergent and whether the ratio is 
constant independently from the gestational age.
6) To evaluate the screening performance of nasal bone length (NBL) and prenasal 
thikness (PT) values and their ratios in the second trimester screening of trisomy 21, 
and to determine the statistical power of this method with the detection rate, the 
sensitivity, the false postivie and the false negativ rate, likelihood ratio, posítive and 
negative predictive values.
7) To determine whether the NBL:PT ratio or its inverse counterpart the PT:NBL ratio 
have better performance in screening second trimester fetuses with Down syndrome.
8) To incorporate these new markers and their ratios into the second trimester anatomy 
scan for combined ultrasound screening of Down-syndrome and other fetal defects.
4. M a te r ia ls  and  m eth od s
4.1. Materials
Women were referred for genetic counselling and second trimester anomaly scans to our 
regional prenatal genetics center because of advanced maternal age (>35 years); positive 
screening results; intermediate risk of combined, triple, or integrated tests and the presence of 
one or more aneuploidy soft markers in previous ultrasound examinations. Women were 
recruited for second-trimester assessment and measurement of the NBL and PT values 
between January 2008 and April 2013. Chromosomal studies from amniotic fluid were carried 
out in the Department of Medical Genetics, University of Szeged. Ultrasound anatomy scans 
were performed at the MEDISONO Fetal and Adult Health Research Center and at the 
Department of Obstetrics and Gynecology, University of Szeged.
The following criteria determined enrollment into the euploid group: singleton viable 
pregnancy, 14-28 weeks of gestation, a lack of maternal disease (such as hypertension, 
toxemia, renal disease, and diabetes mellitus), normal fetal growth, normal amniotic fluid 
volume, diagnosis of a normal fetal anatomy, and newborns without chromosomal or 
structural abnormalities between the fifth and 95th percentile birth weight at delivery.
The study included 1330 euploid and 33 Down syndrome fetuses. The protocol was approved 
by the ethics committee of the University of Szeged. A routine second-trimester anomaly scan 
in weeks 18-23 and a detailed examination of the fetal anatomy within 14-17 and 23-28 
weeks of gestation were performed using a high-resolution 2D transabdominal ultrasound 
scanner (Voluson E8 Expert, GE Healthcare, Milwaukee, WI, USA).
4.2. Methods
4.2.1. Measurement of prenasal thickness and nasal bone length
The facial profile was assessed at the beginning of the scanning sessions to avoid effects of 
fetal movements that could alter the fetal position. Three image acquisitions were obtained 
during one scan session and the best one was used for analysis. I f  it was not successful, then 
the patient came back for another scanning session 30-40 min later. The sonographer was 
blind to the fetal karyotype, and each ultrasound examination was performed before the 
chromosomal study. Nasal bone length(15, 32) and prenasal thickness(38) measurements can
be obtained on the same image if the face of the transducer was positioned parallel to the 
nasal bone. The insonation angle was close to 45°.
The following image settings were used: low gain, medium dynamic contrast, and maximum 
magnification so that the fetal head occupied the entire screen. Images were adjusted to ensure 
correct midsagittal plane (22, 31). Briefly, PT was measured as the shortest distance from the 
lower margin of the frontal bone to the outer surface of the overlying skin. The margins of the 
nasal bone are the proximal and the distal ends of the white ossification line. The NBL(15, 
32) and PT(31) were measured using the same view (Figure 2A and B).
Figure 2 Measurements of nasal bone length and prenasal thickness in euploid (A) and
in a trisomy 21 (B) fetus
4.2.2. Database
Maternal data and sonographic findings were recorded in a database (Astraia Software GmbH, 
Münich, Germany). The ultrasound imaging data were stored in the local Digital Imaging and 
Communications in Medicine (DICOM) format via Astraia. Values of NBL and PT were 
exported to Microsoft Excel (Microsoft Corp., Redmond, WA, USA).
4.2.3. Statistical analysis
Statistical analyses were performed using SigmaPlot (Systat Software Inc., San Jose, CA, 
USA). Scatter plots of NBL and PT with linear polynomial regression lines and percentile 
curves (third and 97th) were created. Similarly, scatter plots of NBL: PT and PT: NBL ratios 
with linear polynomial regression lines and percentile curves (fifth and 95th) were produced. 
Comparisons between euploid and Down syndrome measurements for NBL, PT [in
millimeters (mm) and in multiple of medians (MoMs)], and their ratios (NBL:PT and 
PT:NBL) were performed using the Mann-Whitney U independent samples test. NBL, PT, 
and PT:NBL and NBL:PT ratio correlations were analyzed. No analysis of correlation was 
performed between any other markers.
The mean maternal age in euploid and Down syndrome cases was 30.6 years (16.6-47.1 
years) and 31.5 years (21.1-42.3 years). The mean gestational age was 19.6weeks (14.0- 
28.9weeks) for euploid and 20.3 weeks (15.0-25.6 weeks) for Down syndrome cases (Table
6).
Table 6 Distribution of maternal age, gestational age (GA), nasal bone length (NBL) and
prenasal thickness (PT) in euploid fetuses
Min. Mean Max. SD
Age (year) 16.63 33.59 47.06 ±4.64
GA (week) 14.00 19.57 28.86 ±3.25
NBL (mm) 0.00 5.62 12.00 ±1.63
PT (mm) 1.4 3.88 8.5 ±1.08
The three consecutive NBL and PT measurements lasted 3 to 6 min and were completed 
during the first, the second, and the third attempts in 77%, 19%, and 4% of the cases, 
respectively.
The total number of the screened patients was 1470. Those excluded (107) were the 
following: fetal structural abnormalities (24), multiple pregnancy (35), maternal conditions 
listed in the method (41) and chromosomal abnormalities, such as Turner syndrome (n=1), 
trisomy 18 (n=4) and trisomy 13 (n=2). After exclusion 1330 euploid and 33 Down syndrome 
fetuses remained.
Ultrasound markers found in the Down syndrome group were:increased nuchal fold thickness 
(n=10), cystic hygroma (n=2), cardiac defects (n=9), echogenic intracardiac focus (n=4),mild 
ventriculomegaly (n=4),short femur (n=3), duodenal atresia (n=1),hyperechogenic bowel 
(n=3), pyelectasis-hydronephrosis (n=3), choroid plexus cyst (n=4), sandal gap sign (n=3),and 
midphalanx hypoplasia of the fifth finger (n=4).
All invasive tests were amniocenteses, either because maternal age (>35 years) (18 cases), a 
positive combined test (>1:250) (12 cases), and second-trimester ultrasound soft markers 
(three cases).
5.1. Statistics on the screening performance of this method
A linear increase was observed in the mean NBL and in the mean PT according to increasing 
gestational age between the 14th and 28th weeks (Table 8). Both the NBL and PT alone were 
found to be strong markers (sensitivity of 76% for both markers) for Down syndrome (Figure 
3A and B).
Figure 3 (A) Gestational-age-dependent nasal bone length values in 1330 euploid (black 
filled circles) and 33 Down syndrome (yellow open circles) fetuses. Approximately 76%  
of cases with Down syndrome fell under the third percentile. (B) Gestational-age- 
dependent prenasal thickness values in 1330 euploid (black filled circles) and 33 Down 
syndrome (yellow open circles) fetuses. Approximately 76%  of cases with Down 
syndrome were above the 95th percentile.
The mean NBL:PT ratio showed a gradual increase from 1.48 to 1.79 between the 14th and 
28th weeks of gestation (a 21.2% T1 increase) (Table 8). There was a statistically significant 
difference (p<0.0001) in the NBL:PT ratio between the euploid and Down syndrome groups 
(Figure 4A and B).
Figure 4. (A) Scatterplot of the ratio of nasal bone length to prenasal thickness in 1330 
euploid (black filled circles) and 33 Down syndrome (yellow open circles) fetuses. All 
fetuses, except one, with Down syndrome fell under the fifth percentile. (B) Scatterplot 
of the ratio of prenasal thickness to nasal bone length in 1330 euploid (black filled 
circles) and 33 Down syndrome (yellow open circles) fetuses. All fetuses, except one, with 
Down syndrome were above the 95th percentile.
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A total of 14 out of the 1330 euploid pregnancies and 32 out of the 33 Down syndrome cases 
were under the fifth percentile, with 97% sensitivity, 0.9% false positive rate, and 99% 
specificity. Evaluating the performance of the ratios, there were 32 true positive and one false 
negative Down syndrome cases identified. However, using the NBL:PT ratio, the false 
positive rate was 50% of those using the PT:NBL ratio. Their ratios have different reference 
ranges because of the inverted counterparts, and the reference range of the NBL:PT ratio is 
wider than that of the PT:NBL ratio. The positive and negative cases with the calculated 
sensitivity, specificity, and false positive and negative rate, using NBL, PT, the NBL: PT 
ratio, and the PT:NBL ratio for screening Down syndrome are summarized in Table 7.
Table 7. Statistical characteristics of the performance of the screening for 
Down syndrome using NBL, PT, and their ratios.
NBL PT NBL + PT N BL:PT PT:N BL
Sensitivity (% ) 75.758 75.758 87.879 96.970 96.970
Specificity (% ) 98.120 97.651 97.143 99.098 98.421
False Positive Rate (% ) 1.880 2.349 2.857 0.902 1.579
False Negative Rate (% ) 24.242 24.242 12.121 3.030 3.030
Positive Likelihood Ratio 40.303 32.244 30.758 107.475 61.414
Negative Likelihood Ratio 0.247 0.248 0.125 0.031 0.031
No correlation has been found between PT and NBL with Spearman Rank Order Correlation 
test (SROC =  0.830 at p<0.05) supporting that both markers are independent variables. The 
PT (PT mean:2.0-5.8mm) has lower values than the NBL (NBL mean: 3.0-10.0mm), and PT 
(axPT average=1.066) and NBL (axNBL average=1.084) elevation are also different during 
the second trimester.
Table 8. The mean, the 3rd, and the 97th percentiles of nasal bone length and prenasal thickness and the mean, the 5th, and the 95th percentiles 
of the ratios of nasal bone length to prenasal thickness and prenasal thickness to nasal bone length of euploid fetuses between 14 and 28 weeks of
gestation
Gestational
Age (W eeks)
Nasal Bone Length (mm) Prenasal Thickness (mm) NBL-to-PT Ratio PT-to-NBL Ratio
3rd Percentile Mean 97th Percentile 3rd Percentile Mean 97thPercentile 5th Percentile Mean
95th
Percentile 5th Percentile Mean
95th
Percentile
14 1.867 3.088 4.310 1.265 2.265 3.266 1.023 1.476 1.928 0.486 0.686 0.886
15 2.324 3.545 4.766 1.495 2.496 3.496 1.046 1.498 1.950 0.478 0.678 0.877
16 2.781 4.002 5.223 1.726 2.726 3.726 1.068 1.520 1.972 0.470 0.669 0.869
17 3.239 4.459 5.679 1.957 2.956 3.956 1.090 1.542 1.994 0.461 0.661 0.861
18 3.723 4.943 6.163 2.201 3.200 4.199 1.113 1.565 2.017 0.453 0.652 0.852
19 4.180 5.399 6.619 2.431 3.430 4.429 1.136 1.587 2.039 0.444 0.644 0.844
20 4.636 5.856 7.076 2.661 3.660 4.660 1.158 1.609 2.061 0.436 0.636 0.835
21 5.093 6.313 7.533 2.891 3.891 4.890 1.180 1.632 2.083 0.428 0.628 0.827
22 5.550 6.770 7.990 3.122 4.121 5.120 1.202 1.654 2.105 0.420 0.619 0.819
23 6.033 7.254 8.474 3.365 4.365 5.364 1.225 1.677 2.129 0.411 0.611 0.810
24 6.490 7.711 8.931 3.595 4.595 5.595 1.247 1.699 2.151 0.403 0.602 0.802
25 6.946 8.167 9.388 3.825 4.825 5.825 1.269 1.721 2.173 0.394 0.594 0.794
26 7.403 8.624 9.846 4.055 5.055 6.056 1.291 1.743 2.196 0.386 0.586 0.786
27 7.886 9.108 10.330 4.298 5.299 6.300 1.314 1.767 2.219 0.377 0.577 0.777
28 8.342 9.565 10.788 4.528 5.529 6.531 1.336 1.789 2.242 0.369 0.569 0.769
Correlation 
Coefficient (r) 
(95%  CI)
p =  <0.0001
0.916 (-1 .0 0 0 -0 .9 2 3 ) 0.815 ( -1 .0 0 0 -0 .8 2 9 ) 0.285 ( -1 .0 0 0 -0 .3 2 6 ) -0 .2 4 4  (-0 .2 8 6 -1 .0 0 0 )
Total Increase 
in Percent
346.87% 209.70% 150.29% 258.00% 144.08% 99.96% 30.54% 21.20% 16.25% -2 4 .1 0 % -1 7 .0 5 % -1 3 .1 8 %
At present there are no simple and sensitive second trimester ultrasound or biochemical 
markers for screening trisomy 21 with high performance. The aim of this study was to test the 
value of ultrasound measurements of NBL and PT for screening Down syndrome.
This 2D ultrasound study demonstrates that NBL and PT measurements can easily be carried 
out within the routine second trimester anatomy scans. We confirmed in a potentially high 
risk Caucasian population that both NBL and PT alone are strong markers of Down 
syndrome, with both having a sensitivity of 76%. The combination of these two markers as a 
ratio increased the detection rate to 97% with a 0.9% false positive rate. Furthermore, we 
demonstrated that the NBL:PT ratio performs slightly better than its inverse counterpart. This 
is new that the NBL:PT ratio is a better marker than the PT:NBL ratio for detecting Down 
syndrome fetuses, primarily because it produced less false positive cases, and it can be used in 
cases where the nasal bone is absent. Moreover, the NBL:PT ratio can easily be calculated 
during the scan. I f  the NBL:PT ratio is less than the fifth percentile, a search for other 
aneuploidy soft markers and invasive fetal karyotyping should be considered. In euploid 
fetuses, the NBL, the PT, and the NBL:PT ratio showed a linear increase with advancing 
gestational age (28, 39). However, our data do not support previous observations that the ratio 
is constant throughout the second trimester because the increase is more accelerated in NBL 
than in PT, and their ratio seems to be dependent on the gestational age (40).
The correlation between nasal bone hypoplasia, absent nasal bone and the correct 
measurement of NBL in Down syndrome fetuses between 15 and 22 weeks of gestation was 
published in 2002 (15, 20, 42). The importance of increased PT in second-trimester screening 
for Down syndrome was first reported by Maymon et al. in 2005 and this technique has a 
sensitivity of 70% (28). They combined PT and NBL measurements, yielding a 27% higher 
screening detection rate than NBL alone (43%). Three subsequent studies confirmed the 
association (30,39,40). De Jong-Pleij et al (2012) in a retrospective study, first reported that 
the PT:NBL ratio is a strong marker for Down syndrome. In their analysis of 3D volumes of 
106 euploid and 30 Down syndrome cases (20 cases on 3D volumes and ten cases on 2D 
volumes), the detection rate was 100% with 5% false positive rate (40).
Genetic sonography can substantially increase detection rates for combined and quadruple 
tests, with a more modest increase in sequential protocols (36,37,43). Combining PT and 
biochemical markers yields an 85% detection rate with 5% false positive rate. When nuchal 
fold thickness is added to PT, NBL, and serum markers, the sensitivity increases to 93%(26). 
When PT, NBL, and their ratios, all in MoMs, are combined with the lengths of the second 
and third digits, a 76% detection rate is achieved with a 6.7% false positive rate using a Gin- 
200 risk cutoff (29). The combination of quadruple tests with the measurements of nuchal fold 
thickness and long bones can yield 90% sensitivity at a 3.1% false positive rate (35).
Two-dimensional measurements of NBL(41,44) and PT are feasible in the first trimester(45); 
therefore, the markers examined in that study could also be beneficial for earlier Down 
syndrome detection. Using a marker similar to PT (e.g., frontonasal fold thickness), one 2D 
study showed that the ratio of frontonasal fold thickness to NBL in a Latin American low-risk 
population (1922 pregnancies with four cases of Down syndrome) can easily be obtained 
during the second-trimester anatomy scan (39).
This study presents novel evidence that the NBL:PT ratio is a better marker than the PT:NBL 
ratio for detecting Down syndrome fetuses. Our data indicate that the NBL:PT ratio is 
superior to currently used investigated ultrasound markers alone or in combination with each 
other or even in combination with maternal biochemistry. A limitation of our study can be 
that it was performed on a mixed-risk Caucasian-population. However, a point in favor of this 
study is that it allowed us to test the performance of these markers on a relatively large group 
of fetuses with Down syndrome. This study focused on a Caucasian population, and further 
studies are needed to evaluate the sensitivity of the ratios across different ethnic groups.
Currently, a number of second trimester ultrasound softmarkers for the detection of Down 
syndrome are in use, but none of them are really efficient and realiable. We know from 
preliminary 2D and retrospective 3D ultrasound studies that the ratio of prenasal thickness to 
nasal bone length (PT:NBL) represents a good marker of second-trimester Down syndrome 
fetuses (40).
In this thesis the results of our prospective study is reported about the importance of the 2D 
ultrasound measurements of nasal bone length (NBL) and prenasal soft tissue thickness (PT) 
and their ratios in the second trimester screening for trisomy 21.
We successfully analyzed and characterized these important fetal facial landmarks. In euploid 
fetuses, the NBL:PT ratio showed gradual increase while the PT:NBL ratio demonstrated a 
gradual decrease over time and was more prominent in case of NBL:PT ratio than in its 
inverse counterpart. It was found that both ratios are highly sensitive markers for Down 
syndrome fetuses. The ratio of nasal bone length to prenasal thickness (NBL:PT) had 
performed better than its inverse counterpart for the screening of trisomy 21. Furthermore, we 
examined the feasibility of incorporation of the 2D ultrasound measurements of NBL and PT 
and the NBL:PT and PT:NBL ratios into the second trimester anomaly scan and evaluated 
their screening performance for the detection of Down syndrome.
In conclusion, the nasal bone length (NBL) and prenasal thickness (PT) and their ratios was 
found to be highly sensitive and specific markers for euploid and Down syndrome fetuses and 
their 2D ultrasound measurements have easily been performed and incorporated into the 
second trimester anatomy scan.
6.1. N ew o b serv a tio n s  in  th is  study
1) In the facial profile of euploid and trisomy 21 fetuses a striking difference was 
observed. The nasal bone length (NBL) and prenasal thickness (PT) proved to be a 
sensitive marker for differentiating trisomy 21 and euploid fetuses.
2) We elaborated the method how the fetal nasal bone length (NBL) and prenasal 
thickness (PT) can be obtained and measured in a single volume acquisition (image) 
during the second trimester anatomy scan.
3) Validated normograms have been created for NBL:PT and PT:NBL ratios on the base 
of large number of second trimester euploid pregnancies
4) We first demonstrated and published the gradual increase in nasal bone length (NBL) 
and prenasal thickness (PT) between 14-28 weeks of gestation in a substantially large 
euploid pregnant population in contrast to other investigators who concluded their 
results oppositely from much smaller population.
5) Our data do not support previous observations that the ratio is constant throughout the 
second trimester because the increase is more accelerated in NBL than in PT, and their 
ratio seems to be dependent on the gestational age.
6) We confirmed in a potentially high risk Caucasian population that both NBL and PT 
alone are strong markers of Down syndrome, with both having a sensitivity of 76%. 
The combination of these two markers as a ratio increased the detection rate to 97% 
with a 0.9% false positive rate.
7) We first described in the international literature that the NBL:PT ratio showed a 
better sreening performance than its inverse counterpart.
8) We first published in the international literature that the ultrasound measurements of 
these new markers can sucessfully be incorporated into the second trimester fetal 
anatomy scan
Important note: Highly trained operators, high quality ultrasound machine, and developed 
data processing are considered to be the most important personal and technical conditions for 
performing this level of ultrasound anatomy scan extended with the-measurements of NBL 
and PT.
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ABSTRACT
Objectives To evaluate the feasibility o f incorporating two-dim ensional ultrasound m easurem ents of nasal bone 
length (NBL) and prenasal thickness (PT) into the second-trim ester anom aly scan and to determ ine w hether the N BL:
PT ratio could help in differentiating euploid and Down syndrome fetuses.
Method Two-dim ensional m easurem ents o f NBL and PT were obtained from the midsagittal plane of the fetal head at 
14-28 weeks of gestation in a Caucasian population at risk for aneuploidy. The screening perform ances o f NBL, PT, 
and the ratios N BL : PT and P T : NBL were analyzed in euploid (n = 1330) and Down syndrome (n = 33) fetuses.
Results Nasal bone length and PT alone showed strong correlations with Down syndrome (sensitivity: 76% at 1.88% 
and 2.35%  false positive rate, respectively). However, the N BL :P T  ratio showed an even stronger correlation with 
Down syndrome (false positive rate: 0.9%, sensitivity: 97%). The m ean N BL : PT ratio showed a gradual increase from 
1.48 to 1.79 (a 21.2%  increase) betw een 14 and 28 weeks of gestation.
Conclusion Two-dim ensional ultrasound m easurem ents of NBL and PT, particularly the N BL :P T  ratio, are highly 
sensitive markers for Down syndrome fetuses. © 2014 John Wiley & Sons, Ltd.
Funding sources: N one 
Conflicts of interest: N one  declared
INTRODUCTION
Differences in nasal bone length (NBL), determined by 
ultrasound, have been suggested to differentiate second-trimester 
euploid and Down syndrome fetuses.1-6 From analyses of the 
facial profile, a thickening of the prenasal soft tissue [prenasal 
thickness (PT)] is also apparent in the vast majority of second- 
trimester fetuses with Down syndrome. There is evidence that 
the combination of NBL and PT measurements as a ratio 
improves the detection of fetal Down syndrome by ultrasound.6-10
Despite the multitude of ultrasound soft markers for Down 
syndrome fetuses -  such as increased nuchal fold thickness, cystic 
hygroma, cardiac anomalies, echogenic intracardiac foci, nasal 
bone hypoplasia, ventriculomegaly, widened iliac crest angle, 
short femur/humerus PT, duodenal atresia, echogenic bowel, 
pyelectasis-hydronephrosis, sandal gap sign, choroid plexus cyst, 
and midphalanx hypoplasia of the fifth finger (Appendix 1) -  there 
are no very sensitive ultrasound markers in the second trimester 
that can be used either alone or in combination.11-13 Furthermore, 
these markers may not be present in all affected fetuses, and such 
as all soft markers, they can also be detected in euploid cases.11
Preliminary observations using 2D ultrasound measurements of 
NBL and PT at our tertiary referral center suggested the potential 
for the second-trimester identification of euploid and Down 
syndrome fetuses in a mixed-risk population.14 Therefore, we 
proposed that both markers and their ratios should be incorporated
into the second-trimester fetal anomaly scan for a reliable, cheap, 
and efficient screening of Down syndrome. The current prospective 
study examined the clinical value of 2D ultrasound measurements 
of NBL, PT, and their ratios for differentiating euploid and Down 
syndrome fetuses in the second trimester (in an at-risk population).
METHODS
Women were referred for genetic counseling and second- 
trimester anomaly scans to our regional prenatal genetics center 
because of advanced maternal age (>35  years); positive screening 
results; intermediate risk of combined, triple, or integrated tests; 
and the presence of one or more aneuploidy soft markers in 
previous ultrasound examinations. W omen were recruited for 
second-trimester assessment and measurem ent of the NBL and 
PT values between January 2008 and April 2013. Informed consent 
was obtained from the mothers before examination at the 
MEDISONO Fetal and Adult Health Research Center or at the 
Department of Obstetrics and Gynecology in Szeged, Hungary.
The following criteria determined enrollment into the euploid 
group: singleton viable pregnancy, 14-28 weeks of gestation, a 
lack of maternal disease (such as hypertension, toxemia, renal 
disease, and diabetes mellitus), norm al fetal growth, norm al 
amniotic fluid volume, diagnosis of a norm al fetal anatomy, 
and newborns without chromosomal or structural abnormalities 
between the fifth and 95th percentile birth weight at delivery.
The study included 1330 euploid and 33 Down syndrome 
fetuses. The protocol was approved by the ethics committee of 
the University of Szeged. A routine second-trimester anomaly scan 
in weeks 18-23 and a detailed examination of the fetal anatomy 
within 14-17 and 23-28 weeks of gestation were performed using 
a high-resolution 2D transabdominal ultrasound scanner 
(Voluson E8 Expert, GE Healthcare, Milwaukee, WI, USA). The 
facial profile was assessed at the beginning of the scanning 
sessions to avoid effects of fetal movements that could alter the 
fetal position. Three image acquisitions were obtained during 
one scan session, and the best one was used for analysis. I f  it 
was not successful, then the patient came back for another 
scanning session 30-40 min later. The sonographer was blind to 
the fetal karyotype, and each ultrasound examination was 
performed before the chromosomal study.
Nasal bone length1,10 and PT9 m easurem ents can be 
obtained on the sam e image if the face of the transducer was 
positioned parallel to the nasal bone. The insonation angle 
should be close to 45°. The following im age settings were 
used: low  gain, m edium  dynam ic contrast, and  m axim um  
m agnification so that the fetal h ea d  occup ied  the entire 
screen. Im ages were ad justed to ensure correct m idsagittal 
plane and sharp m argins o f the skin and  the nasal bone. The 
diencephalon, nasal bone, lips, maxilla, and m andible were 
used as reference points for the correct m easurem ents of 
NBL and PT in the m idsagittal p lane.3,9 Briefly, PT was 
m easured  as the shortest d istance from  the low er m argin of 
the frontal bone to the outer surface of the overlying skin. 
The margins o f the nasal bone are the proxim al and the distal 
ends o f the white ossification line. The NBL and PT were 
m easured using the sam e view (Figure 1A and B).
M aternal data and sonographic findings were recorded in a 
database (Astraia Software GmbH, M unich, Germany). The 
ultrasound imaging data were stored in the local Digital 
Imaging and Communications in Medicine (DICOM) format 
via Astraia. Values of NBL and PT were exported to Microsoft 
Excel (Microsoft Corp., Redmond, WA, USA). Statistical analyses 
were performed using SigmaPlot (Systat Software Inc., San Jose, 
CA, USA). Scatter plots of NBL and PT with linear polynomial 
regression lines and percentile curves (third and 97th) were 
created. Similarly, scatter plots o f N BL:PT and P T:N BL ratios 
with linear polynomial regression lines and percentile curves 
(fifth and 95th) were produced. Comparisons between euploid 
and Down syndrome m easurem ents for NBL, PT [in millimeters
(mm) and in multiple o f medians (MoMs)], and their ratios 
(N BL:PT and PT:N BL) were performed using the M ann­
W hitney U independent samples test. NBL, PT, and P T : NB and 
N B :P T  ratio correlations were analyzed. No analysis of 
correlation was performed between any other markers.
RESULTS
The total num ber of the screened patients was 1470. The mean 
maternal age in euploid and Down syndrome cases was 30.6 years 
(16.6-47.1 years) and 31 .5years (21.1-42.3years). The mean 
gestational age was 19.6 weeks (14.0-28.9 weeks) for euploid and 
20.3 weeks (15.0-25.6  weeks) for Down syndrom e cases.
Those excluded were the following: fetal structural
abnormalities (24), multiple pregnancy (35), maternal conditions 
listed in the m ethod (41), and chromosomal abnormalities, such 
as Turner syndrome (n = 1), trisomy 18 (n = 4), and trisomy 13 
(n = 2) (Appendix 2).
Ultrasound markers found in the Down syndrome group were 
increased nuchal fold thickness (n =10), cystic hygroma (n = 2), 
cardiac defects (n = 9), echogenic intracardiac focus (n = 4), mild 
ventriculomegaly (n = 4), short femur (n = 3), duodenal atresia 
(n = 1), hyperechogenicbowel (n = 3), pyelectasis-hydronephrosis 
(n = 3), choroid plexus cyst (n = 4), sandal gap sign (n = 3), and 
midphalanx hypoplasia of the fifth finger (n = 4) (Appendix 3).
All invasive tests were amniocenteses, either because maternal 
age (>35  years) (18 cases), a positive combined test (> 1 :2 5 0 ) (12 
cases), and second-trimester ultrasound soft markers (three cases).
The three consecutive NBL and PT m easurem ents lasted  3 to 
6 min and were com pleted during the first, the second, and the 
third attempts in 77%, 19%, and 4% o f the cases, respectively.
There was a statistically significant difference (p <  0.0001) in 
the N BL : PT ratio betw een the euploid and Down syndrome 
groups. Both the NBL and PT alone were found to be strong 
markers (sensitivity of 76% for both markers) for Down 
syndrome (Figure 2A and B).
A linear increase was observed in the m ean NBL, the m ean PT, 
and the m ean N BL: PT ratio according to increasing gestational 
age between the 14th and 28th weeks. The m ean N BL: PT ratio 
showed a gradual increase from 1.48 to 1.79 between the 14th 
and 28th weeks of gestation (a 21.2% increase) (Table 1). A total 
of 14 out of the 1330 euploid pregnancies and 32 out of the 33 
Down syndrome cases were under the fifth percentile, with 97% 
sensitivity, 0.9% false positive rate, and 99% specificity (Table 2.)
Figure 1 Examples of nasal bone length and prenasal thickness measurements obtained in euploid (A) and Down syndrome (B) fetuses
Evaluating the perform ance of the ratios, there were 32 true 
positive and one false negative Down syndrome cases 
identified. However, using the N BL: PT ratio, the false positive 
rate was 50% o f those using the P T : NBL ratio (Figure 3A and 
B). The positive and negative cases with the calculated 
sensitivity, specificity, and false negative rate, using NBL, PT, 
the NBL : PT ratio, and the PT : NBL ratio for screening Down 
syndrome are summarized in Table 2.
No correlation has been found between PT and NBL with 
Spearman Rank Order Correlation test (SROC =  0.830 at 
p <  0.05) supporting that both markers are independent 
variables. The PT (PT mean: 2.0-5.8 mm) has lower values than 
the NBL (NBL mean: 3 .0-10.0 mm), and PT (axPT average = 1.066) 
and NBL (axNBL average = 1.084) elevation are also different 
during the second trimester. Their ratios have different reference 
ranges because o f the inverted counterparts, and the reference 
range of the N BL: PT ratio is wider than that o f the P T : NBL ratio.
DISCUSSION
This 2D ultrasound study demonstrates that NBL and PT 
measurem ents can easily be incorporated into routine second- 
trimester anatomy scans. We confirmed in a potentially high risk 
Caucasian population that both NBL and PT alone are strong 
markers of Down syndrome, with both having a sensitivity of 
76%. The com bination o f these two markers as a ratio increased 
the detection rate to 97% with a 0.9% false positive rate.
Furtherm ore, the N BL : PT ratio performs slightly better than 
its inverse counterpart. This is new  that the N BL: PT ratio is a 
better m arker than the PT : NBL ratio for detecting Down 
syndrome fetuses, primarily because it produced less false 
positive cases, and it can be used in cases where the nasal bone 
is absent. Moreover, the N BL : PT ratio can easily be calculated 
during the scan. If the N BL :P T  ratio is less than the fifth 
percentile, a search for other aneuploidy soft markers and 
invasive fetal karyotyping should be considered.
In euploid fetuses, NBL, PT, and the N BL : PT ratio showed a 
linear increase with advancing gestational age. However, our 
data do not support previous observations7,15 that the ratio is 
constant throughout the second trim ester because the increase
is m ore accelerated in NBL than in PT, and their ratio seem s to 
be dependent on the gestational age (Table 1).15
The correlation betw een nasal bone hypoplasia, absent nasal 
bone, and the correct m easurem ent of NBL in Down syndrome 
fetuses betw een 15 and 22 weeks of gestation was published in 
2002.1-3 The im portance of increased PT in second-trim ester 
screening for Down syndrome was first reported by M aymon 
etal. in 2005, and this technique has a sensitivity of 70%.7 They 
com bined PT and NBL m easurem ents, yielding a 27% higher 
screening detection rate than NBL alone (43%). Three 
subsequent studies confirm ed the association.8,15,16
De Jong-P leije tal., in a retrospective study, first reported that 
the PT : NBL ratio is a strong marker for Down syndrome. In their 
analysis of 3D volumes of 106 euploid and 30 Down syndrome 
cases (20 cases on 3D volumes and ten cases on 2D volumes), 
the detection rate was 100% with a 5% false positive rate.16
G enetic sonography can substantially increase detection 
rates for com bined and quadruple tests, with a m ore m odest 
increase in sequential p rotocols.17 Com bining PT and 
biochem ical m arkers yields an 85% detection rate with a 5% 
false positive rate. W hen nuchal fold thickness is added to 
PT, NBL, and serum  m arkers, the sensitivity increases to 
93% .18 W hen PT, NBL, and their ratios, all in MoM s, are 
com bined with the lengths o f the second and third digits, a 
76% detection rate is achieved w ith a 6.7% false positive rate 
using a 1-in-200 risk cutoff.19 The com bination o f quadruple 
tests with the m easurem ents of nuchal fold thickness and long 
bones can yield 90%  sensitivity at a 3.1% false positive rate.20
Two-dimensional measurements of NBL21 and PT are feasible in 
the first trimester22; therefore, the markers examined in that study 
could also be beneficial for earlier Down syndrome detection.
Using a m arker similar to PT (e.g., frontonasal fold thickness), 
one 2D study showed that the ratio o f frontonasal fold thickness 
to NBL in a Latin American low-risk population (1922 
pregnancies with four cases of Down syndrome) can easily be 
obtained during the second-trim ester anatom y scan.15
This study presents novel evidence that the N BL: PT ratio is a 
better marker than the P T : NBL ratio for detecting Down 
syndrome fetuses. Our data indicate that the N BL: PT ratio is
Figure 2 (A) Gestational-age-dependent nasal bone length values in 1330 euploid (black filled circles) and 33 Down syndrome (black open 
circles) fetuses. Approximately 76% of cases with Down syndrome fell under the third percentile. (B) Gestational-age-dependent prenasal 
thickness values in 1330 euploid (black filled circles) and 33 Down syndrome (black open circles) fetuses. Approximately 76% of cases with 
Down syndrome were above the 95th percentile
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Table 2 Statistical characteristics of the performance of the screening for Down syndrome using NBL, PT, their multiple of medians and their ratios
NBL PT NBL+PT NBL MoMs PT MoMs NBL:PT PT : NBL
Sensitivity (%) 7 5 .7 5 7 5 .7 5 87.88 6 9 .7 0 6 9 .7 0 9 6 .9 7 9 6 .9 7
Specificity (%) 9 8 .1 2 9 7 .6 5 9 7 .1 4 9 8 .3 4 9 6 .8 4 9 9 .1 0 9 8 .4 2
False positive rate (%) 1.88 2.35 2 .86 1.65 3.16 0 .9 0 1.58
False negative rate (%) 2 4 .2 4 2 4 .2 4 12.12 30.30 30.30 3.03 3.03
NBL, nasal bone length; PT, prenasal thickness; MoMs, multiple of medians.
Figure 3 (A) Scatterplot of the ratio of nasal bone length to prenasal thickness in 1330 euploid (black filled circles) and 33 Down syndrome 
(black open circles) fetuses. All fetuses, except one, with Down syndrome fell under the fifth percentile. (B) Scatterplot of the ratio of prenasal 
thickness to nasal bone length in 1330 euploid (black filled circles) and 33 Down syndrome (black open circles) fetuses. All fetuses, except one, 
with Down syndrome were above the 95th percentile
superior to currently used investigated ultrasound markers alone 
or in com bination with each other or even in com bination with 
m aternal b iochem istry . A lim itation of our study is that it 
was perform ed on a m ixed-risk C aucasian population. 
However, a point in favor of this study is that it allowed 
us to test the perform ance of these markers on a relatively 
large group of fetuses with Down syndrom e. This study 
focused on a Caucasian population, and further studies 
are needed to evaluate the sensitivity of the ratios across 
different ethnic populations.
CONCLUSION
In conclusion, 2D ultrasound m easurem ents of NBL and PT 
can easily be perform ed within the second-trim ester anom aly 
scan, and their ratios appear to be highly sensitive and specific 
markers for euploid and Down syndrome fetuses. The 2D 
m easurem ents o f these markers and their ratios can be 
incorporated into the second trim ester anatom y scan.
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WHAT'S ALREADY KNOW N ABOUT THIS TOPIC?
Preliminary 2D  and retrospective 3D  studies show that the ratio of 
prenasalthlckness to nasalbone length (PT: NBL) is a strong marker 
o f second-trimester Down syndrome fetuses.
WHAT DOES THIS STUDY ADD?
The ratio of nasal bone length to prenasalthickness (NBL: PT) had 
performed better than its inverse counterpart for the screening of trisomy 21. 
In euploid fetuses, the PT: NBL and the NBL: PT ratios showed 
gradualincreases over time.
Two-dimensionalultrasound measurements of NBL and PT were 
successfully incorporated into the routine second-trimester anomaly scan.
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APPENDIX 1. Ultrasound soft markers for Down syndrome fetuses 
in the second trimester
Nuchal fold thickness (NF)
Cystic hygromc 
Cardiac anomalies
Echogenic intracardiac foc i/go lf ball sigr 
Nasal bone hypoplasia (NBL)
Increased prenasal thickness (PT
W idened iliac crest angle
Short femur
Short humerus
Ventriculomegaly
Duodenal atresia
Pyelectasis-hydronephrosis
Echogenic bowel
Sandal gap sign
Choroid plexus cyst
Midphalanx hypoplasia of the fifth finger
APPENDIX 2. Excluded euploid pregnancies
Number of cases (N)
Multiple viable pregnancy 35
MATERNAL disease 18
Abnormal amniotic fluid volume 10
Fetal structural abnormalities 24
Chromosomal or structural abnormalities 7
Abnormal birth weight at delivery(<5th and >95th) 41
Fetal loss/death in second and third trimester 3
APPENDIX 3. Trisomy 21 cases scan results
Number of cases (N)
Increased nuchal fold thickness 10
Cardiac defects 9
Echogenic intracardiac focus 4
Mild ventriculomegaly 4
Choroid plexus cyst 4
Midphalanx hypoplasia of the fifth finger 4
Hyperechogenic bowel 3
Pyelectasis-hydronephrosis 3
Short femur 3
Sandal gap sign 3
Cystic hygroma 2
7
8.
APPENDIX 4. Interobserver and intraobserver variability
Table A . Interobserver and intraobserver variability  of nasal bone length (NBL) and prenasal thickness (PT) in absolute (mm) and 
relative (%) values at 95% limits of agreement (LoA) and their confidence intervals (CI)
Intraobserver ( n = 1.330)
Measuremenl Mean relative difference 95% CI 95% Lower LoA 95% CI 95% Upper LoA 95% CI
NBL 0.59% 0.398%  lo 0.786% -6 .4 8 % 0.398%  lo 0.786% 7.66% 7.330%  lo 7.993%
PT 0.97% 0.787%  lo 1.163% -5 .8 6 % -6 .1 8 5 %  lo -5 .5 4 3 % 7.81% 7.493%  lo 8.134%
Measuremenl Mean difference 95% CI 95% Lower LoA 95% CI 95% Lower LoA 95% CI
NBL (mm) 0 .028 0 .0 1 6 4  lo 0 .0 4 03 - 0 .4 0 6 -0 .4 2 6 8  lo - 0 .3 8 6 0 0 .463 0 .4 4 2 7  lo 0 .4 8 35
PT (mm) 0 .0 3 9 0 .0 3 2 0  lo 0 .0 4 6 4 -0 .2 2 3 -0 .2 3 5 1  lo -0 .2 1 0 5 0.301 0 .2 8 8 9  lo 0 .3 1 35
Interobserver (n = 102)
Measuremenl Mean relative difference 95% CI 95% Lower LoA 95% CI 95% Upper LoA 95% CI
NBL -0 .1 4 % -0 .7 6 9 %  lo 0.494% -6 .4 7 % -7 .5 5 1 %  lo -5 .3 8 6 % 6.19% 5.112%  lo 7.276%
PT -0 .1 1  % -0 .6 4 9 %  lo 0.436% -5 .5 5 % -6 .4 7 7 %  lo -4 .6 1 7 % 5.33% 4.404%  lo 6.264%
Measuremenl Mean difference 95% CI 95% Lower LoA 95% CI 95% Upper LoA 95% CI
NBL (mm) - 0 .0 1 0 - 0 .0 6 7  lo 0 .0 4 7 - 0 .4 4 2 - 0 .5 4 0  lo - 0 .3 4 4 0.421 0 .3 2 4  lo 0 .5 1 9
PT (mm) - 0 .0 0 4 - 0 .0 3 0  lo 0 .023 - 0 .2 0 4 - 0 .2 4 9  lo - 0 .1 5 9 0 .1 9 7 0.151 lo 0 .2 4 2
Intraobserver and interobserver variability Results:
These are preliminary data for intraobserver and  interobserver 
variability; a Bland-Altm an analysis23 was used to describe 
intraobserver and interobserver variability.
Methodology: Two images were saved: one with calipers and
one without calipers. To assess interobserver 
variability, the measurements of these two 
markers were repeated after the scanning by Conclusion 
another operator, who remeasured the markers 
as previously described.The intraobserver 
variability analysis was performed on the three 
images, which were taken during the scan session.
The limits of agreement (LOA: 95% CI) were 
-6 .48%  to 7.66% and -5 .8 6 %  to 7.81% for NBL 
and PT, respectively. The respective 
interobserver variability 95%  lim its of 
agreem ent were -6 .4 7 %  to 6.19%  and 
-5 .5 5 %  to 5.44%  (Appendix Table A). There 
is a very low and not significant difference 
that has b een  confirm ed.
There is a need to  have further studies on the 
m easurem ent education and on the 
intraobserver and interobserver variability of 
PT and NBL, and have it published as a 
separate article.
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A prenazális lágyrész-vastagodás 
a 21-es triszómia ultrahangjele 
a második trimeszterben
Szabó Andrea dr.1'3, Szili Károly d r.1, Szabó János Tamás dr.2, Isaszegi 
Dóra dr.1, Horváth Emese d r.1, Sikovanyecz János dr.2, Szabó János dr.1,3
'Szegedi Tudományegyetem Általános Orvosi Kar, Orvosi Genetikai Intézet, Szeged (Igazgató: Szabó 
János dr., egyetemi tanár)
2Szegedi Tudományegyetem Általános Orvosi Kar, Szülészeti és Nőgyógyászati Klinika, Szeged (Igazgató: 
Pál Attila dr., egyetemi tanár)
3MediSono Magzati és Felnőtt Egészségkutató Központ, Szeged 
Összefoglaló
Célkitűzés: A 21-es triszómia szűrése az első trimeszterben a tarkóredő mérésével és a biokémiai marke­
rek, nevezetesen a szabad b-hCG és a PAPP-A, segítségével nagy hatékonyságú módszer, míg a második 
trimeszterben - megbízható ultrahangjelek hiányában - igen nagy kihívást jelent a szakemberek számára. 
Az utóbbi években a prenazális lágyrész vastagságának mérésére terelődött a figyelem a második trimesz­
terben. Tanulmányunk célja az említett, ultrahanggal mérhető jel normogramjának és szűrővizsgálati haté­
konyságának meghatározása euploid és 21-es triszómiában szenvedő magzatok esetén.
Betegek és módszerek: A  méréseket prospektiv vizsgálatok keretében, euploid és 21-es triszómiában szenve­
dő magzatokon végeztük el a várandósság 16-24 hetében. A  prenazális lágyrész-vastagság mérését a mag­
zati arcprofil közép-szagittális síkjában, hasi ultrahangvizsgálattal (Voluson E8 és Voluson 730 Expert, 
G E Medical Systems, Zipf, Austria) 2D-ben végeztük. Prenazális lágyrész-vastagságnak az os frontale alsó 
csontos pólusától a felette lévő bőr külső felszíne közötti legrövidebb távolságot tekintettük. Az adatokat 
Astraia programban és excel file-ban rögzítettük. A  következő statisztikai módszereket alkalmaztuk: reg­
ressziós analízis, Shapiro-Wilk teszt, Kolmogorov-Smirnov-teszt és a Mann-Whitney U-teszt, SigmaStat 
statisztikai programban.
Eredmények: Ötszáz euploid és tizenkilenc 21-triszómiás magzat adatainak elemzése során megállapítottuk, 
hogy a különbség a két csoport értékei között nem véletlenszerű. A  Mann-Whitney U-teszt alapján a kü­
lönbség a két csoport között statisztikailag szignifikánsnak bizonyult. A  21-es triszómiában szenvedő mag­
zatok túlnyomó többségében a prenazális lágyrész-vastagság az euploid magzatok 95 percentilise fölé esik. 
Következtetés: A prenazális lágyrész-vastagság értéke a várandósság második trimeszterében önmagában 
is igen hatékony ultrahangjele a 21-es triszómiának. Alkalmazásával még hatékonyabbá válhat a Down- 
szindróma szűrése.
Kulcsszavak: Down szindróma, 21-es triszómia, ultrahangszűrés, második trimeszter, prenazális 
lágyrészvastagság, orrcsonthosszúság
Szabó A , Szili K , Szabó JT, Isaszegi D , Horváth E, Sikovanyecz J, Szabó J 
The prenasal thickness a good second trimester marker of trisomy 21.
Summary
Objective: Down-syndrome screening in the first trimester based on increased nuchal translucency (N T) 
and biochemical markers o f free b-hCG and PAPP-A has been established to be a very efficient method. 
However, in the absence o f efficient ultrasound marker, the screening for trisomy 21 is a great challenge in 
the second trimester. Therefore in the last several years research has been focused on the measurement of
the prenasal soft tissue thickness and the nasal bone length. In this period the purpose o f our study was 
the evaluation of the prenasal thickness in the second trimester screening for trisomy 21.
Patients and Methods: In a prospective study prenasal thickness (PT) was measured in euploid and in 
trisomy 21 fetuses with transabdominal 2D  ultrasound (G E Voluson E8 and G E - 730). Measurement o f 
the prenasal thickness was performed in mid-sagittal plane o f the fetal head identifying the appropriate 
landmarks. Prenasal thickness was defined as the shortest distance from the lower edge of the os frontale to 
the outer surface of the overlying skin. Data were registered in Astraia programme and in excel files. For 
statistical methods regression analysis, Shapiro-Wilk test, Kolmogorov-Smirnov-test and Mann-Whitney 
U-test were used in Sigmastat, statistical software.
Results: We analyzed the results o f 500 euploid and 19 fetuses with trisomy 21. The difference in the 
median P T  values between the two groups was greater than it would be expected by chance. There was 
a statistically significant difference (P = <0,001) according to Mann-Whitney Rank Sum Test. The majority 
of the P T  values of 19 fetuses with trisomy 21 fell above the 95th percentile o f the euploid group. 
Conclusion: The ultrasound measurement o f prenasal soft tissue thickness alone was found to be highly 
efficient marker for trisomy 21. Using this sonographic marker in the second trimester the trisomy 21 
screening may become more effective.
Keywords: Down syndrome, trisomy 21, second trimester, ultrasound screening, prenasal thickness, nasal
boné length
Bevezetés
A  21-es triszómia az első trimeszterben a tarkóredő vas­
tagsága (nuchal translucency, N T), az orrcsont (nasal boné) 
vizsgálata és a biokémiai markerek alapján nagy hatékony­
sággal szűrhető, míg a második trimeszteri ultrahangszű­
rés - megbízható jelek hiányában - igen nagy kihívást je ­
lent a szakemberek számára [1-4].
Bár a 21 -es triszómiának a második trimeszterben is 
vannak jól meghatározott ultrahangjeíei, amelyek felhívják 
a figyelmet a szindróma lehetőségére, az érintett magzatok 
egy része az euploidoktól alig mutat eltérést, így emiatt 
az esetek jelenős részét a második trimeszterben sem is­
merik fel [4]. Ismert tény az is, hogy a szűrés eredményes­
sége jelentősen függ a vizsgáló jártasságától [5].
Az utóbbi években, főként a magzati arcprofil elemzése 
vezetett oda, hogy finomabb jelek, mint például az orr­
csont hypoplasia, aplasia, az orrgyök-homlokcsont szöglet 
és az úgynevezett prenazális lágyrész-vastagodás (PLV) - 
angol nevén prenasal thickness (PT) - mérése hasznos ada­
tokat szolgáltathat a kórkép második trimeszteri szűrésé­
ben [6, 7].
A tanulmányunk célja volt, hogy prospektiv vizsgálat 
során összehasonlítsuk az euploid és a 21-es triszómiában 
szenvedő magzatok esetén a prenazális lágyrész- vastagsá­
got és megállapítsuk ennek jelentőségét a Down szindró­
ma szűrésében.
Betegek és módszerek
Ötszáz euploid és tizenkilenc, a későbbiekben citogeneti­
kai módszerrel igazolt, 21-es triszómiában szenedő mag­
zat P T  mérését végeztük el prospektív tanulmány kereté­
ben, a várandósság 16-24 hete között.
A  prenazális lágyrész-vastagság mérését a magzati 
arcprofil közép-szagittális síkjában 2 dimenziós hasi ult­
rahangvizsgálattal (Voluson E8 és Voluson 730 Expert, 
G E  Medical Systems, Zipf, Austria) végeztük. Az orr­
hegy, az orrcsont, az ajkak, a maxilla, a mandibula és 
a diencephalon egy síkba állítása után a beeső ultrahang­
nyalábbal az orrcsontot merőlegesen pásztáztuk. Beállítási 
nehézség esetén legfeljebb 30 fokos homlokirányú eltérést 
tartottunk megengedhetőnek. A prenazális lágyszövet 
vastagságnak az os frontale alsó csontos pólusától a felette 
lévő bőr külső felszíne közötti legrövidebb távolságot te­
kintettük. A  nagyító (zoom) funkcióval a képet akkorára 
növeltük, hogy a magzat arcprofilja a képernyőnek csak­
nem az egészét elfoglalja (1. ábra). Ugyanebből a beállítás­
ból az orrcsont hosszúsága is mérhető, így ezzel a mérési 
módszerrel a hiányzó orrcsont esetén is meg lehet mérni 
a prenazális lágyrész- vastagságot.
Statisztikai analízis
A  P T  értékeket az Astraia szülészeti és nőgyógyásza­
ti software adatbázisából (astraia G M BH , Germany, 
Münich) kérdeztük le és ellenőrzés céljából MicroSoft 
Excel programba importáltuk, majd statisztikai elemző 
programmal vizsgáltuk annak érdekében, hogy regressziós 
analízist végezzünk és hogy meghatározzuk az eloszlást és 
annak normalitási fokát, valamint a gesztációs kor (GA) 
és a prenazális lágyrész-vastagság (PT) közötti kapcso­
latot. A  Shapiro-Wilk normálitási vizsgálat bizonyítot-
1. ábra 19 hetes euploid magzat prenazális lágyrész-vastagsága. A fehér 
vonal jelzi a mérendő lágyrész-vastagságot és a helyes mérést.
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3. ábra Euploid magzatok prenazális lágyrész-vastagság nomogramja 
a terhességi napok függvényében
ta a normál eloszlást az euploid és a 21-es triszómiában 
szenvedő magzatok között. A  delta értékre ellenőrzés cél­
jából a Kolmogorov-Smirnov-tesztet alkalmaztuk, amely 
megerősítette feltevésünket azáltal, hogy a delta értékek 
eloszlása mind az euploid, mind a 21-es triszómiás mag­
zatokon szignifikáns korrelációt mutatott.
Mann-Whitney-U-teszttel hasonlítottuk össze 
az euploid és a 21-es triszómiában szenvedő magzatok 
PT-értékeit. Az adatok statisztikai elemzéséhez SigmaStat 
(SigmaStat és SigmaPlot; San Jose, California, USA) 
programot használtunk, amely szignifikáns értékeket mu­
tatott (p < 0,005 ) és polynomális súlyozott eloszlás sze­
rint ábrázoltuk. Ezután a grafikonokat és a diagramokat 
szerkesztés és publikálás céljából Excel 2007 programba 
(Microsoft Corp., Redmond, WA, USA) importáltuk.
Eredmények
Ötszáz euploid és tizenkilenc, 21-es triszómiában szenve­
dő magzatnál végeztük el a méréséket a várandósság 16­
24. hete között a 2009-2011-es években. A  vizsgálatban
2. ábra 19 hetes 21-es triszómiás magzat prenasalis lágyrész-vastagsága.
A  fehér vonal jelzi a mérendő lágyrész-vastagságot és a helyes mérést.
1 4 0  1 4 5  1 5 0
G e s z tá c ió s  kor (n a p )
4. ábra A  21-es triszómiás magzatok prenazális lágyrész-vastagságának 
(PLV) értékei az euploid nomogramon
euploid egyes terhességeket tanulmányoztunk, ahol nem 
volt sem kromoszóma-, sem strukturális rendellenesség. 
Az 1. ábra egy euploid magzat, a 2. ábra pedig egy 21-es 
triszómiában szenvedő magzat prenazális lágyrész-vastag­
sága mérésének módját, a mérőkeresztek (caliper) helyes 
elhelyezését mutatja.
A  terhességi kort a prenazális lágyrész-vastagság függ­
vényében ábrázolva egy normogramot kaptunk (J. ábra). 
A  normogramról leolvasható, hogy a prenazális lágyrész­
vastagság terhességi korral arányosan növekszik. Hasonló 
normogramon ábrázoltuk a 21-es triszómiában szenvedő 
magzatok PT-értékeit. A  21-es triszómiás magzatok PT- 
értéke a 95 percentilis fölé esett, jelentősen meghaladva 
az euploid magzatok prenazális lágyrész-vastagságát (4. 
ábra).
Megbeszélés
A  prenazális lágyrész-vastagodás (PT) jelentőségére 
triszómiás magzatoknál először Maymon és mtsai. (2005) 
hívták fel a figyelmet [6]. A  14 -27. hét között húsz, 21-
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es triszómiában szenvedő és 500 euploid magzat eseté­
ben mérték a prenazális lágyrész- vastagságot. M egál­
lapították, hogy a 21-es triszómiás magzatoknál a PT  
lényegesen nagyobb, mint az ép kariotípussal rendelkező 
magzatokban. Tanulmányuk szerint a prenazális lágyrész­
vastagság és az orrcsont hosszúságának együttes mérésével 
70 %-os volt a felismerési arány, 5 %-os álpozitív arány 
mellett, míg az orrcsont hosszának mérésével önmagában 
csak 43 %-os szűrési hatékonyságot értek el. A  két marker 
együttes alkalmazását hatékonyabbnak találták a Down- 
szindróma szűrésében.
Persico és mtsai. (2008) 135 euploid és 26,
cytogenetikailag bizonyított 21-es triszómiás magzat 
arcprofiijának elemzése kapcsán, a 16-24. hét közötti 
prenazális lágyrész-vastagság méréseinek eredményeit kö­
zölték [7]. Megállapították, hogy a 21-es triszómiás mag­
zatok 73,1%-ánál a PT  95 percentilis feletti tartományba 
esett. Arra a következtetésre jutottak, hogy a P T  vizsgá­
lata érzékeny módszer a Down-szindróma második tri- 
meszteri szűrésében. A  21-es triszómia egyéb ultrahang­
jelei, mint a ventriculomegalia, nuchalis oedema, hiányzó 
orrcsont, vagy szívdefektus nem befolyásolták ezt a haté­
konyságot.
Maymon és mtsai. korábbi eredményüket azzal egészí­
tették ki, hogy az anyai életkoron és a PT-értéken alapuló 
táblázatot készítettek a triszómia kockázatának „bedside” 
értékelése céljából [8]. Vizsgálatuk szerint jól elkülönül­
nek a 21-es triszómiás és az euploid magzatok multiples- 
of-median (MoM)-ban kifejezett médián PT-értékei: 
a 21-es triszómiásoknál 1,31 M oM  volt, míg 1,01 M oM  
az euploid magzatok esetén adódott.
Migue/ez és mtsai. a prenazális lágyrész-vastagság mé­
rését biokémia markerekkel kombinálva a 21-es triszómia 
magas detekciós arányát találták [9].
De Jong-Pleij és mtsai., 106 euploid és harminc, 21-es 
triszómiában szenvedő magzatban mérték a prenazális 
lágyrész-vastagságot, az orrcsont hosszúságát 3D-ben 
a második és harmadik trimeszterben [10]. Az elmentett 
képek utólagos elemzése során azt találták, hogy a P T  és 
az orrcsont hosszúsága (nasal boné legth, NBL) a terhességi 
korral együtt nő és a kettő aránya 21-es triszómiás mag­
zatoknál 95 percentilis fölé esett.
Prospektív tanulmányunk megerősíti az irodalmi ada­
tokat, miszerint a prenazális lágyrész-vastagság (PLV) 
a terhességi korral arányosan növekszik euploid mag­
zatok esetében. A prenazális lágyrész-vastagság a 21-es 
triszómiában szenvedő magzatok jelentős részében 95 
percentilis felett van. Ez a viszonylag könnyen mérhető 
ultrahangjel rutinszerűen alkalmazható a várandósság má­
sodik trimeszterében és jelentősen növeli a 21-es triszómia 
méhen belüli szűrésének hatékonyságát.
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A new scoring system for the diagnosis of placenta accreta by 
ultrasound
Y. Gilboa, M. Spira, E. Sivan, E. Schiff, R. Achiron 
O B G Y N , Sheba M edical Center, H od Hasharon, Israel
Objectives: Our aim was to determine the accuracy of a novel simple 
scoring system based on sonographic markers in differentiating 
between low and high risk forplacenta accreta (PA).
M ethods: All women who were referred to the Sheba Medical 
Center due to suspected PA were included, underwent a detailed 
ultrasound examination. A score was given based on the common 
sonographic findings of PA: loss of the hypoechoic retroplacental 
zone and placental lacunae. A score of 0 - 2  was defined as low risk 
and 3 was defined as high risk. Patients assigned to the high risk 
category underwent prophylactic pelvic artery catheterization before 
cesarean section and embolization if needed, whereas patients in the 
low risk category underwent simple cesarean section.
Results: 71 women were included. PA was diagnosed clinically 
during surgery in 28 women, o f whom 31 had a score of 3, and ruled 
out in 43 women, of whom only one had a score of 3. The sensitivity, 
specificity, positive predictive value and negative predictive value of 
our ultrasound-based scoring system in predicting PA were 90% , 
97.5% 93 and 95%  respectively.
Conclusions: A simple scoring system based on ultrasound alone can 
identify accurately a high risk population for PA who can benefit 
from prophylactic pelvic artery catheterization and embolization.
O P 3 4 :  S C R E E N I N G  F O R  A N E U P L O I D Y  
A N D  C O N S U L T I N G  I N  T H E  S E C O N D  
T R I M E S T E R
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Extracellular chromosome 21: derived microRNAs in 
maternal circulation: evaluation of their diagnostic potential 
for screening of Down syndrome
I. Hromadnikova1, K. Kotlabova1, J. Doucha2, D. Chudoba3, 
P. Calda4, K. Dlouha5
1 Department o f  Molecular Biology and Cell Pathology, 
Charles University, Third Faculty o f  Medicine, Prague 10 , 
Czech Republic; 2Clinic o f  Obstetrics and Gynecology, 
Charles University, Second Faculty o f  Medicine, Prague 5, 
Czech Republic; 3Department o f  Biology and M edical 
Genetics, Charles University, Second Faculty o f  Medicine, 
Prague 5, Czech Republic; 4Clinic o f  Obstetrics and 
Gynecology, Charles University, First Faculty o f  Medicine, 
Prague 2, Czech Republic; 5Institute for the Care o f  the 
M other and Child, Prague 4, Czech Republic
Objectives: In this pilot study we focused on the detection of extra­
cellular microRNAs in maternal circulation, whose genes are located 
on human chromosome 21 (miR-99a, let-7c, miR-125b-2, miR-155 
and miR-802). Subsequently, we studied if plasm atic concentrations 
and/or expression profile of extracellular chromosome 21-derived 
m icroRNAs would distinguish between pregnancies bearing euploid 
foetuses and those affected with Down syndrome.
Methods: 12 women with normal course of gestation (mean 
16.4 weeks, median 16.0 weeks), 12 pregnancies bearing Down 
syndrome foetus (mean 18.2 weeks, median 18.5 weeks) and 6 
non-pregnant individuals were involved in the retrospective study. 
RNA enriched for small RNAs (including microRNAs) was isolated 
from 1 ml of plasm a sample. Consequently relevant microRNA was 
transcribed into cDNA using specific stem-loop primer and detected 
by specific real-time PCR assay.
Results: Commercial systems enabled reliable detection of 4 out of 5 
extracellular chromosome 21-derived microRNAs (miR-99a, let-7c, 
miR-125b-2 and miR-155). Expression profile of extracellular miR- 
99a, miR-125b-2 and miR-155 was significantly higher in the cohort
of pregnant women than in non-pregnant individuals. Also plasmatic 
levels of miR-99a and miR-125b-2 were significantly increased 
in pregnant women. Unfortunately, the concentrations and gene 
expression of extracellular chromosome 21-derived microRNAs 
(miR-99a, let-7c, miR-125b-2 and miR-155) did not differ between 
the cohorts of pregnancies bearing euploid foetuses and those 
affected with Down syndrome.
Conclusions: Analysis of extracellular chromosome 21-derived 
microRNAs does not distinguish between pregnancies with euploid 
and aneuploid foetuses and has no benefit for screening programmes. 
Acknowledgement: The work w as supported by GAUK no. 434011.
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Objectives: Down-syndrome screening in first trimester based on 
increased nuchal translucency (NT) and biochemical markers is 
very effective. However, in second trimester it is a great challenge 
in the absence of efficient ultrasound marker. During the last years 
several reports suggested that prenasal soft tissue thickness and nasal 
bone hypoplasia could be sonographic markers for Down-syndrome 
screening. We measured and compared the prenasal thickness (PT) 
in euploid and in fetuses with Down-syndrome prospectively. 
Methods: Transabdominal 2D ultrasound (Voluson E8) measure­
ment of the prenasal thickness w as performed in mid-sagittal plane 
of the fetal head identifying diencephalon, tip of the nose, lips, 
maxilla, nasal bone. The insonation angle was 90° to the nasal bone 
or maximum 30 degree of lifting to the frontal bone was allowed. 
The prenasal thickness was defined as the shortest distance from the 
lower edge of the os frontale to the outer surface of the overlying 
skin. The nasal bone can also be determined from this view. The 
magnification of the view (zoom) w as zoomed such that the fetal 
profile occupied the whole screen.
Results: We analyzed the results of 810 euploid and 19 fetuses 
with trisomy 21 measured between the 1 6 -2 3  gestational weeks. In 
euploid fetuses the mean PT (and NBL) increased steadily between 
16 and 33 weeks’ gestation. The difference in the median PT values 
between the two groups was greater than it would be expected by 
chance. There was a statistically significant difference (P <  0.001) 
according to Mann-Whitney Rank Sum Test. All of the 19 fetuses 
with trisomy 21 the PT values were lower than 5th percentile curve 
of the euploid group.
Conclusions: The ultrasound measurement of prenasal soft tissue 
thickness w as found to be highly efficient marker alone for trisomy 
21. The Down-syndrome screening with this marker can become 
more effective.
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Objectives: Down syndrome screening in first trimester based on 
nuchal translucency (NT) and biochemical markers is very efficient, 
while in second trimester it is a great challenge. Measurement of 
nasal bone length and prenasal soft tissue thickness w as found 
to be promising facial landmarks in second trimester screening
for Down-syndrome. We prospectively measured and compared 
prenasal soft tissue thickness (PT) and nasal bone length (NBL) in 
second trimester euploid and trisomy-21 fetuses.
Methods: Using 2D abdominal ultrasound the measurement of PT 
and N BL w as taken in mid-sagittal plane of the fetal head identifying 
diencephalon, tip of the nose, lips, maxilla, mandible, nasal bone in 
weeks 1 6 -2 3  in the second trimester. The PT is the shortest distance 
from the bottom edge of the os frontale to the outer surface of the 
overlying skin. The nasal bone w as measured from this view. The 
insonation angle w as 90° (perpendicular) to the nasal bone. NBL/PT 
ratios of euploid fetuses between 1 6 -2 3  weeks were analyzed and 
validated by Shapiro-Wilke test. We used software (SigmaStat 12 &  
SigmaPlot 12) to create graphs, the regression line and the percentiles 
curves (5th- 2 5 th- 7 5 th- 9 5 th) have been calculated from the normal 
values. We used the normal graphs to visualize and compare trisomy 
21 cases to euploids (P <  0.0001).
Results: Analyzes of 810 euploid and 19 fetuses with trisomy 
21 measured between the 16 -2 3  gestational weeks were done. 
In euploid fetuses the mean PT and N BL increased steadily between 
16 and 33 weeks’ gestation. The difference in the median PT values 
between the two groups was greater than would be expected by 
chance. There w as a statistically significant difference (P =  <0.001) 
Mann-Whitney Rank Sum Test. All of the 19 fetuses with trisomy 
21 the NBL/PT values were lower than 5th percentile curve of the 
euploid group.
Conclusions: CIn fetuses with trisomy 21 the NBL/PT ratio was 
significantly lower compared to euploid ones. The NBL/PT ratio 
was found to be very sensitive and specific marker for trisomy 2.
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Objectives: Study of incidence, fetal development, anatomy and birth 
of single umbilical artery (SUA) fetuses during seven years. 
Methods: A retrospective study of 6 148 low risk singleton 
pregnancies. Number of umbilical arteries was determined using 
color flow imaging of the fetal pelvis between 11+ 0  and 13+ 6  
gestation weeks. Medical, obstetric ultrasound records and postnatal 
maternal questionnaires were reviewed.
Results: SUA was antenataly diagnosed in 15 pregnancies (incidence 
0.24% ), and isolated SUA in 73%  of the cases (n =  11). 93.3%  
of the pregnancies resolved in live birth. In one case pregnancy 
w as terminated due to multiple anomalies (omphalocela, anasarca, 
bilateral choroid plexus cyst, regurgitation of atrioventricular 
valves). Amniocentesis w as performed in 5 cases of the US verified 
isolated SUA. In all the results were normal. Screening for neural 
abnormalities showed choroid plexus cyst in 13%  of the cases, 
dilated posterior ventricle in 6 .7% , same as absent corpus callosum. 
Fetal echocardiography revealed no increase in incidence of heart 
defects while hyperechogenic focus of the left ventricle prompted 
genetic exploration and yielding normal results in one case. 
Antenatal pyelon abnormalities were detected in 6.7% . Estimated 
fetal weight was distributed as follows: below 10th percentile 15.4% , 
1 0 -4 9 th percentile 49 .1% , 5 0 - 9 0 *  percentile 30.8%  and above 
90th percentile 7 .7% . At birth 4 fetuses had pelvic presentation, and 
Cesarean section performed in all (26.7% ). Postnatal questionnaires 
revealed presence of birth defects in two babies (absence of an ear 
lobe in the first, atresia of the biliary duct in the second) which were 
not diagnosed prenatally.
Conclusions: Vigilant and frequent antenatal monitoring of 
SUA fetuses focusing on fetal anatomy is warranted, knowing 
chromosopathies are linked to anatom ical abnormalities. Incidence 
may be statistically small, but the consequences of prenatally 
undiagnosed abnormalities on the quality of life are great.
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Objectives: Single umbilical artery (SUA) is found in 1% of 
pregnancies. It can be diagnosed in the first and second trimester. 
The two vessel cord is associated with chromosomal trisomies and 
a number of structural abnormalities such as spina bifida, renal and 
heart defects, intrauterine growth retardation, intrauterine demise 
and impaired school achievements. Some severe defects can only be 
diagnosed after birth.
Methods: Referrals of couples with single umbilical artery were made 
from the Department of Obstetrics and Gynecology of University and 
from the regional obstetric hospitals and private clinics. A database 
w as established and analyzed with statistical methods. Associated 
anomalies were classified according to severity and organ system 
occurrence.
Results: Eighty eight couples with diagnosis of SUA attended our 
Prenatal Clinic between 2005 and November, 2011. Sixteen of them 
were first trimester diagnosis, and 4 out of them proved to be three 
vessels (3-VC) at the control examination. In 59 cases the SUA 
w as recognized in weeks 1 9 -2 3 , two of them proved to be false 
diagnosis. Mean age w as 29,86 years, mean body weight w as 69 kg. 
Male/female ratio was 46/36. Genetic advice was accepted by most 
of the pregnant, except three, and one of them gave birth to a 
newborn with trisomy 21. Chromosomal aberration was revealed in 
two cases: a trisomy 18 and a trisomy 21. Kidney and heart defects 
were found in four cases. A lethal tracheal stenosis was revealed 
month after birth.
Conclusions: M ajority of SUAs are recognized in weeks 18-23 . 
Genetic counseling is suggested and chromosomal study is indicated 
except in very low risk cases for chromosomal defects calculated 
according to ultrasound and biochemical tests. Our data shows that 
the risk of trisomies is high in cases of SUA and the clinician should 
consider for sevear adverse fetal outcome, too.
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Objectives: Polyhydramnios occur in 1 -2 %  of pregnancies. While 
the majority is idiopathic, conditions like gestational diabetes 
(GDM ), congenital malformations and viral infections may be 
associated. This work presents etiology of polyhydramnios and 
the respective perinatal outcome.
Methods: Etiology and perinatal outcome o f pregnancies diagnosed 
with polyhydramnios at the Department of Obstetrics and 
Gynecology, Medical University Graz, Austria, between 2003 and 
2011 were retrospectively analyzed.
Results: 976 affected pregnancies were identified, from which 166 
(17.0% ) were excluded due to incomplete data. 152 (18.8% ) 
of the remaining 810 cases were associated with GD M , 73 
(9.0% ) with congenital malformations and 24 (3.0% ) with viral 
infections, while 560 (69.1% ) were idiopathic. The latter had the 
best outcome, while those with malformations had higher rates 
of preterm delivery, lower Apgar scores and low birth weight. 
The group with viral infections had nearly the same outcome 
as the idiopathic group. Elective Caesarean sections were equally
IV.
Identified fetal heart malformations in the first trimester. Experiences after 1000 examination
Tibor Elekes, Gyula Csermely, Krisztina Kádár, Gábor Keszthelyi, László Molnár, Júlia Déri 
RMC-Fetal Medicine Centre, Budapest
Objectives:
According to the literature, 80-90%  of congenital heart defects (CHD] are a product of low-risk 
pregnancies. The international datas also demonstrate that in a high-risk population succesful 
transabdominal ultrasound assessment of the fetal heart can be carried out at 11-13 weeks by well 
trained obstetricians in >95% of cases and that >90% of major cardiac defects can be identified at this 
gestation. The aim of this study was to evaluate the feasibility and accuracy of fetal echocardiography 
at the first trimester extended screening performed by well trained obstetricans in a group of 
unselected, consecutive pregnants.
Patients and Method:
In this retrospective study, fetal echocardiography was performed between January 2010 and March 
2012. Within this period we examined 1007 unselected, consecutive patients, singletons, twins and 
triplets, (1033 fetuses] presented in our private fetal medicine centre for first trimester extended 
screening. The vast majority of examinations were carried out transabdominally using a 4-8 MHz 
convex transducer (Accuvix V20, Samsung-Medison]. The examinations were performed by two 
obstetricians with extensive experience in first and second trimester screen. Digital videoclips and 
photo documentations of the cardiac scan were stored. All abnormal findings during the routine 
assessment were reviewed by a fetal cardiologist, and a genetic counsellor was also involved in the 
consultation with the patients. Follow-up US evaluations during the second trimester were offered to 
all patients, the high risk group was also referred to fetal cardiologist.
In the group of 1007 unselected pregnancies 983 were singeletons, 22 were twins and 2 were triplets. 
The median maternal age was 33,4 (range 20-44] years. Among the 1033 fetuses included in this study 
the obstetricans identified 6 cases with severe heart malformations: two AV septal deffect, one VSD, 
one pulmonary stenose, one pulmonary vein transposition and one aortic stenose(?]. In the group 
classified as normal only 353 patients chose our centre for subsequent second trimester scan. Among 
them, we identified cardiac defect in two cases: one aortic stenose at 17 weeks, and one dislocated 
heart, related to a right sided diaphragmatic hernia at 20 weeks.
Conclusion:
First trimester assesment of the fetal heart is not only feasible, but also very profitable in an 
unselected population, when performed by experienced obstetricians. To determine our centre's 
degree of accuracy in the first trimester fetal heart screening, further data analysis is necessary. 
However, altough most types of severe CHDs can be diagnosed early in pregnancy, some may become 
apparent later in gestation. Our experiences also suggest that all cases classified as abnormal should be 
referred to cardiologist; either for better evaluation of the abnormality or to confirm the diagnosis, in 
order to give more appropiate counselling to the parents.
Ultrasound screening for Down-syndrome in the second trimester: the prenasal thickness
1Szabó Andrea, 1Szili Károly, 2Szabó Ján os Tamás, 'Isaszegi Dóra, H orváth Emese,
2Sikovanyecz János, 1Szabó János
1SZTEÁOK Orvosi Genetikai Intézet, Szülészeti és 2Nőgyógyászati Klinika, Szeged
Objective:
Down-syndrome screening in first trimester based on nuchal translucency (NT] and biochemical 
markers is very effective, while in second trimester the screening is a great challenge. Despite of the 
fact that Down-syndrome has ultrasound soft markers, which are remarkable, a small proportion of of 
fetuses with Down-syndrome do not show marked alterations from euploid ones. That's why some
Results:
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cases of Down-syndrome is not detected even in the second trimester. In the last years, especially 
analyzing the fetal face called attention to nasal bone hypoplasia, aplasia, and thickening of the 
prenasal soft tissue indicating them, useful tools in sonographic screening for trisomy 21. Our aim was 
to elaborate a better screening protocol. We measured prenasal soft tissue thickness and nasal bone 
length in euploid and aneuploid fetuses.
Methods:
The measurement of the prenasal thickness was taken in a mid-sagittal plane of the fetal head 
indentifying lips, maxilla, mandible, diencephalon, nasal bone and tip of the nose with abdominal 
ultrasound. The insonation was perpendicular ( 90°] to the nasal bone or maximum a 30 degree 
inclination towards the os fron tale  was acceptable. The prenasal thickness is the shortest distance 
from the bottom part of the os fron tale  to the outer surface of the overlying skin. The nasal bone can 
also be measured from this view. The magnification of the view (zoom] should be such that the fetal 
profile occupy the two-third of the image.
Statistical analysis:
The data were analyzed according to polynomial distribution.
Results: We analyzed the results of 500 euploid and 19 fetuses with 21 trisomy measured between the 
16-24 gestational weeks. In fetuses with trisomy 21 the prenasal thickness was found to be 
significantly larger, i e it was above 95 percentile in trisomy 21 fetuses.
Conclusion:
The prenasal soft tissue thickness measured in the nasal bridge is a strong marker for trisomy 21. 
Using these marker the Down-syndrome screening can become more effective.
Septostomy vs. amniocentesis in case of twin-to-twin transfusion syndrome
Ján os Sikovanyecz
Department o f  Obstetrics and Gynecology, University o f  Szeged
Twin to twin transfusion syndrome (TTTS] is a disease of the placenta that effect only identical twin 
pregnancies. The placenta contains abnormal blood vessels which connects the circulations of the 
twins. Depending on the number, type and direction of the connecting vessels, blood can be transfused 
disproportionately from one twin (the donor] to the other twin (recipient]. The recipient twin 
becomes overloaded with blood with the consequence of heart failure and polyhydramnion. The 
transfusion causes the donor twin to have decreased blood volume, which leads to growth retardation 
and poor urinary output as a consequence of oligohydramnion. The polyhydramnion causes 
prematurity very often. The fetal and neonatal loss rate is very high, without treatment it's mortality 
rate is 90-100% . The neonatal morbidity rate is 10-30% resulted from fetal hypoxia. The frequency of 
TTTS is 15% among monochorionic twins.
Treatments:
1. Reduction amniocentesis: Removal of the excessive amniotic fluid from the sac of the recipient 
twin.
2. Septostomy: Creation of a hole in the membrane between the babies' sacs using a needle. This 
procedure allows the amniotic fluid to be equalized between the two amniotic sacs. Septostomy can 
slow down the development of polyhydramnion hereby avoiding prematurity. Amnionreduction and 
septostomy are not causal treatment of TTTS.
3. Laser ablation of the placental anastomotic vessels: Laser ablation of the communicating 
vessels on the placenta between the twin fetuses. This is a causal treatment of TTTS, but fetal and 
neonatal loss rate is similarly high to the previous procedure. Other disadvantage of the procedure is 
the need of a special and expensive instrument.
The author would like to share his experience about amnionreduction and septostomy.
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